Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents

Patent 4721669 Issued on January 26, 1988. Estimated Expiration Date:

January 26, 2005. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Method for the direct analysis of sickle cell anemia
Patent #: 4395486
Issued on: 07/26/1983
Inventor: Wilson , et al.

Intercalating agents specifying nucleotides Patent #: 4547569
Issued on: 10/15/1985
Inventor: Letsinger , et al.

Inventor

Barton, Jacqueline K.

Application

No. 06/693023 filed on 01/18/1985

US Classes:

435/6, Involving nucleic acid204/157.72, Hetero nitrogen ring contains at least two hetero atoms424/617, Heavy metal or compound thereof536/25.4, Separation or purification of polynucleotides or oligonucleotides546/88, Phenanthrolines (including hydrogenated)987/5Devoid of any cobalt atom directly bonded to carbon (15/06B)

Examiners

Primary: Kepplinger, Esther M.
Assistant: Jay, Jeremy M.

Attorney, Agent or Firm

White; John P.

International Classes

C07F 15/06 (20060101)
C12Q 1/68 (20060101)
C07F 15/00 (20060101)
C07H 23/00 (20060101)
C07H 21/00 (20060101)
C07D 471/00 (20060101)
C07D 471/04 (20060101)

Abstract

This invention concerns a coordination complex and salts and optically resolved enantiomers thereof, of the formula (R)3 --M, wherein R comprises 1,10-phenanthroline or a substituted derivative thereof, M comprises a suitable transition metal, e.g. ruthenium(II) or cobalt(III), and R is bonded by M by a coordination bond.The complexes of this invention are useful in methods for labeling, nicking and cleaving DNA. The lambda enantiomer of complexes of this invention is useful in methods for specifically labeling, detecting, nicking and cleaving Z-DNA.The complexes may also be used in a method for killing tumor cells and may be combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition for the treatment of tumor cells in a subject. The invention further concerns methods for treating a subject afflicted with tumor cells.

Other References

Barton, J. K. et al, J. Am. Chem. Soc., vol. 106, No. 8, 1984, pp. 2466-2468
Barton, J. K. et al, J. Am. Chem. Soc., vol. 106, No. 7, 1984, pp. 2172-2176
Barton, J. K. et al, Proc. Natl. Acad. Sci. USA, vol. 81, Apr. 1984, pp. 1961-1965
Barton, J. K. et al, J. Am. Chem. Soc., vol. 104, No. 18, 1982, pp. 4967-4969
Yamagishi, A., J. Chem. Soc., Chem. Commun., vol. 10, 1983, pp. 572-573
Chang, C. H. et al, Biochemistry, vol. 21, 1982, pp. 6332-6334
Chang, C. H. et al, Biochemistry, vol. 23, 1984, pp. 2268-2274
Pommier, Y. et al, Biochemistry, vol. 23, No. 14, 1984, pp. 3194-3201
Pope, L. M. et al, J. Biol. Chem., vol. 257, Oct. 1982, pp. 12121-12128